ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 408,64
-0,30%
Dow Jones
42 297,12
0,86%
DAX
20 132,85
-0,44%
Brent Oil
80,025
-0,32%
Bitcoin
95 043,70
0,57%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Esperion Therapeutics Inc (ESPR) Cours

Esperion Therapeutics Inc

Esperion Therapeutics Inc (ESPR)

NASDAQ
2,28
-0,06
(-2,56%)
Fermé 14 Janvier 10:00PM
Retardé de 15 minutes
2,27
-0,01
(-0,44%)
Après les heures de négociation: 1:50AM
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
2,27
Prix Achat
2,26
Prix Vente
2,28
Volume échangé
7 799 211
2,15 Fourchette du Jour 2,325
1,58 Plage de 52 semaines 3,94
Cap du marché
447,27M
Clôture Veille
2,34
Ouverture
2,29
Dernière Transaction
150
@
2.27
(formt)
Dernière heure de transaction
Volume financier
US$ 17 216 378
VWAP
2,2075
Volume moyen (3 m)
5 966 921
Actions en circulation
197 035 171
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-2,16
Bénéfice par action (BPA)
-1,06
Chiffre d'affairess
116,33M
Bénéfice net
-209,25M

À propos de Esperion Therapeutics Inc

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializi... Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.esperion.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Esperion Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker ESPR. Le dernier cours de clôture d'Esperion Therapeutics était de US$2,34. Au cours de la dernière année, les actions de Esperion Therapeutics ont été négociées dans une fourchette de prix de US$ 1,58 à US$ 3,94.

Esperion Therapeutics compte actuellement 197 035 171 actions en circulation. La capitalisation boursière d'Esperion Therapeutics est de US$461,06 million. Esperion Therapeutics a un ratio cours/bénéfice (ratio PE) de -2.16.

ESPR Dernières nouvelles

Plus de nouvelles

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.

– Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease – ANN ARBOR, Mich., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion...

09 Janvier 2025
GlobeNewswire Inc.

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

ANN ARBOR, Mich., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 43rd Annual J.P. Morgan Healthcare Conference...

02 Janvier 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

18 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

18 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

18 Décembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

18 Décembre 2024
Edgar (US Regulatory)

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt – – New Facility Represents...

18 Décembre 2024
GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities

17 Décembre 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

17 Décembre 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

17 Décembre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.14.608294930882.172.3552.1242446712.21534716CS
40.052.252252252252.222.542.100144223102.24436323CS
120.2311.27450980392.043.941.840159669212.49614601CS
26-0.21-8.467741935482.483.941.5847877212.2801268CS
52-0.79-25.81699346413.063.941.5861614902.35466919CS
156-1.75-43.53233830854.028.870.737621402.70399536CS
260-57.21-96.183591123159.4879.9890.726010385.79576097CS

ESPR - Frequently Asked Questions (FAQ)

What is the current Esperion Therapeutics share price?
The current share price of Esperion Therapeutics is US$ 2,27
How many Esperion Therapeutics shares are in issue?
Esperion Therapeutics has 197 035 171 shares in issue
What is the market cap of Esperion Therapeutics?
The market capitalisation of Esperion Therapeutics is USD 461,06M
What is the 1 year trading range for Esperion Therapeutics share price?
Esperion Therapeutics has traded in the range of US$ 1,58 to US$ 3,94 during the past year
What is the PE ratio of Esperion Therapeutics?
The price to earnings ratio of Esperion Therapeutics is -2,16
What is the cash to sales ratio of Esperion Therapeutics?
The cash to sales ratio of Esperion Therapeutics is 3,88
What is the reporting currency for Esperion Therapeutics?
Esperion Therapeutics reports financial results in USD
What is the latest annual turnover for Esperion Therapeutics?
The latest annual turnover of Esperion Therapeutics is USD 116,33M
What is the latest annual profit for Esperion Therapeutics?
The latest annual profit of Esperion Therapeutics is USD -209,25M
What is the registered address of Esperion Therapeutics?
The registered address for Esperion Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Esperion Therapeutics website address?
The website address for Esperion Therapeutics is www.esperion.com
Which industry sector does Esperion Therapeutics operate in?
Esperion Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
PHIOPhio Pharmaceuticals Corporation
US$ 6,50
(284,62%)
281,98M
SLRXSalarius Pharmaceuticals Inc
US$ 3,65
(133,23%)
120,26M
VRMEVerifyMe Inc
US$ 4,1575
(63,04%)
57,6M
ATPCAgape ATP Corporation
US$ 1,9645
(55,91%)
84,16M
AVGRAvinger Inc
US$ 0,8248
(46,47%)
9,78M
EHGOEshallgo Inc
US$ 1,2408
(-62,06%)
6,74M
CMTLComtech Telecommunications Corporation
US$ 2,3491
(-43,12%)
4,37M
SVMHSRIVARU Holding Ltd
US$ 0,0352
(-43,04%)
184,27M
LAESSEALSQ Corporation
US$ 3,35
(-41,54%)
89,92M
NMHINatures Miracle Holding Inc
US$ 1,12
(-38,80%)
735,08k
GCTKGlucoTrack Inc
US$ 0,1493
(27,61%)
685,02M
PHIOPhio Pharmaceuticals Corporation
US$ 6,50
(284,62%)
281,98M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,0627
(-28,83%)
232,25M
NVDANVIDIA Corporation
US$ 133,23
(-1,97%)
204,68M
RGTIRigetti Computing Inc
US$ 6,0344
(-32,43%)
192,21M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
ESPR
Esperion Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés